Cytochrome P-450 2D6 and 2C19 polymorphisms and length of hospitalization in psychiatry

Clinical Laboratory

Volumn 52, Issue 5-6, 2006, Pages 237-240

  Kropp, Stefan ^a,c   Lichtinghagen, Ralf ^a   Winterstein, Kathrin ^a,c   Schlimme, Jann ^a,c   Schneider, Udo ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Department of Psychiatry and Psychotherapy   (Germany)

^c Clinic for Psychiatry Psychotherapy and Psychosomatics   (Germany)

Author keywords

CYP2C19; CYP2D6; Cytochrome P450; Depression; Drug metabolism; Neuroleptics; Pharmacogenetics; Polymorphism pharmacogenomics; Schizophrenia

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; PSYCHOTROPIC AGENT; CYP2C19 PROTEIN, HUMAN; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; CAUCASIAN; GENETICS; MENTAL HOSPITAL; METABOLISM; MIDDLE AGED; PILOT STUDY;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; DEPRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HOSPITALS, PSYCHIATRIC; HUMANS; LENGTH OF STAY; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PILOT PROJECTS; POLYMORPHISM, GENETIC; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA;

EID: 33745899617     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Kirchheiner J, Brøsen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjoqvist F, Spina E, Brockmöller J: CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173-192.
2. Goldstein JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-355.
3. Sachse C, Brockmöller J, Bauer S, Roots I: Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-295.
4. Köhnke MD, Griese EU, Stösser D, Gärtner I, Barth G: Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 2002; 35: 116-118.
5. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989; 45: 889-90.
6. Johansson I, Lundqvist E, Dahl M-L, Ingelman-Sundberg M. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996; 6: 351-5
7. Scordo MG, Spina E: Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 2002; 3: 201-218.
8. Shulman RW, Özdemir V: Psychotropic Medications and Cytochrome P450 2D6: pharmacokinetic considerations in the elderly. Can J Psychiatry 1997; Suppl 3: 4S-9S.
9. Tatro DS: Drug interaction facts 2002. St. Louis: Facts and comparisons; 2002.
10. Kroemer HK, Eichelbaum M: "It's the genes, stupid. "Molecular basis and clinical consequences of genetic cytochrome P450 2D6 polymorphisms. Life Sci 1995; 56: 2285-2298.
11. Ensom MH, Chang TK, Patel P: Pharmacogenetics. The therapeutic drug monitoring of the future?. Clin Pharmacokinet 2001; 40: 783-802.
12. De Leon J, Barnhill J, Rogers T, Boyle J, Chou WH, Wedlund PJ: Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital. Am J Psychiatry 1998; 155: 1278-1280.
13. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, Martin WL, Hays LR, Wedlund PJ: The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996; 60: 522-534.